(旧版)大腸癌治療ガイドライン

 
文献

 
1) Kudo S. Endoscopic mucosal resection of flat and depressed types of early colorectal cancer. Endoscopy. 1993;25(7):455-61.
2) 井上晴洋,竹下公矢,遠藤光夫,他:早期胃癌に対する内視鏡的粘膜切除術―透明プラスチックキャップを用いる方法 (EMRC)―.Gastroenterol Endosc 1993;35:600-607.
3) 小山恒男:Endoscopic surgery―切開・剥離 EMR―Hook ナイフを中心に.東京,日本メディカルセンター;2003.
4) Tanaka S, Haruma K, Oka S, et al. Clinicopathologic features and endoscopic treatment of superficially spreading colorectal neoplasms larger than 20 mm. Gastrointest Endosc. 2001;54(1):62-6.
5) 田中信治,岡 志郎,茶山一彰:表面型早期大腸癌の内視鏡的粘膜切除術―適応・切除手技選択と治療成績―.Gastroenterol Endosc 2004;46:243-52.
6) Tanaka S, Haruma K, Oh-E H, et al. Conditions of curability after endoscopic resection for colorectal carcinoma with submucosally massive invasion. Oncol Rep. 2000;7(4):783-8.
7) Kitajima K, Fujimori T, Fujii S, et al. Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study. J Gastroenterol. 2004;39(6):534-43.
8) 武田 純,長廻 紘,奥山 隆,他:5.大腸sm癌の取り扱い.b.内視鏡治療後の追加手術が必要な条件.武藤徹一郎(監),渡辺英伸,杉原健一,多田正大(編),大腸疾患 NOW 2004,東京,日本メディカルセンター;2004:60-9.
9) Ueno H, Mochizuki H, Hashiguchi Y, et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology. 2004;127(2):385-94.
10) Japanese Society for Cancer of the Colon and Rectum: Multi-Institutional Registry of Large Bowel Cancer in Japan, Cases treated in 1995-1998. Vol. 17 (1999), Vol. 18 (2000), Vol. 21 (2001), Vol. 24 (2003)
11) 大腸癌研究会:大腸癌取扱い規約,第6版,東京,金原出版;1998
12) Mentges B, Buess G, Schafer D, et al. Local therapy of rectal tumors. Dis Colon Rectum. 1996;39(8):886-92.
13) Ono C, Yoshinaga K, Enomoto M, et al. Discontinuous rectal cancer spread in the mesorectum and the optimal distal clearance margin in situ. Dis Colon Rectum. 2002;45(6):744-9; discussion 742-3.
14) Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery--the clue to pelvic recurrence? Br J Surg. 1982;69(10):613-6.
15) Weeks JC, Nelson H, Gelber S, et al. Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. JAMA. 2002;287(3):321-8.
16) Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med. 2004;350(20):2050-9.
17) 望月英隆:腹膜播種を伴う大腸癌.上西紀夫,田中雅夫(編),消化器癌の外科治療,東京,中外医学社;2001:100-2.
18) 正木忠彦,武藤徹一郎,安富正幸:大動脈周囲リンパ節の実態―第44回大腸癌研究会アンケート調査報告.日本大腸肛門病会誌 1997;50:318-30.
19) Murata S, Moriya Y, Akasu T, et al. Resection of both hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer. 1998;83(6):1086-93.
20) Kobayashi K, Kawamura M, Ishihara T. Surgical treatment for both pulmonary and hepatic metastases from colorectal cancer. J Thorac Cardiovasc Surg. 1999;118(6):1090-6.
21) Rodgers MS, McCall JL. Surgery for colorectal liver metastases with hepatic lymph node involvement: a systematic review. Br J Surg. 2000;87(9):1142-55.
22) Martin LW, Warren RS. Current management of colorectal liver metastases. Surg Oncol Clin N Am. 2000;9(4):853-76; discussion 877-8.
23) Penna C, Nordlinger B. Colorectal metastasis (liver and lung). Surg Clin North Am. 2002;82(5):1075-90, x-xi.
24) Kato T, Yasui K, Hirai T, et al. Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum. 2003;46(10 Suppl):S22-31.
25) Fortner JG, Silva JS, Golbey RB, et al. Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer. I. Treatment by hepatic resection. Ann Surg. 1984;199(3):306-16.
26) Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery. 1986;100(2):278-84.
27) Ekberg H, Tranberg KG, Andersson R, et al. Pattern of recurrence in liver resection for colorectal secondaries. World J Surg. 1987;11(4):541-7.
28) Nordinger B, Jaeck D, Guiguet M, et al: Surgical resection of hepatic metastases. Multicentric retrospective study by the French Association of Surgery. In: Nordinger B, Jaeck D, editors, Treatment of hepatic metastases of colorectal cancer. Paris.: Springer-Verlag;1992:129-46.
29) Cady B, Jenkins RL, Steele GD Jr, et al. Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. Ann Surg. 1998;227(4):566-71.
30) Yamamoto J, Sugihara K, Kosuge T, et al. Pathologic support for limited hepatectomy in the treatment of liver metastases from colorectal cancer. Ann Surg. 1995;221(1):74-8.
31) Elias D, Cavalcanti A, Sabourin JC, et al. Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases. J Surg Oncol. 1998;69(2):88-93.
32) Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997;15(3):938-46.
33) Kokudo N, Miki Y, Sugai S, et al. Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. Arch Surg. 2002;137(7):833-40.
34) Lambert LA, Colacchio TA, Barth RJ Jr. Interval hepatic resection of colorectal metastases improves patient selection. Arch Surg. 2000;135(4):473-9; discussion 479-80.
35) Beckurts KT, Holscher AH, Thorban S, et al. Significance of lymph node involvement at the hepatic hilum in the resection of colorectal liver metastases. Br J Surg. 1997;84(8):1081-4.
36) Nakamura S, Suzuki S, Konno H. Resection of hepatic metastases of colorectal carcinoma: 20 years' experience. J Hepatobiliary Pancreat Surg. 1999;6(1):16-22.
37) Regnard JF, Grunenwald D, Spaggiari L, et al. Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg. 1998;66(1):214-8; discussion 218-9.
38) Robinson BJ, Rice TW, Strong SA, et al. Is resection of pulmonary and hepatic metastases warranted in patients with colorectal cancer? J Thorac Cardiovasc Surg. 1999;117(1):66-75; discussion 75-6.
39) 加藤知行,安井健三,平井 孝,他:大腸癌肝転移に関する研究―大腸癌の肝転移に対する外科療法―.武藤徹一郎(監),大腸疾患 NOW 2004,東京,日本メディカルセンター;2004:89-104.
40) Nordlinger B, Vaillant JC, Guiguet M, et al. Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. Association Francaise de Chirurgie. J Clin Oncol. 1994;12(7):1491-6.
41) Yamamoto J, Kosuge T, Shimada K, et al. Repeat liver resection for recurrent colorectal liver metastases. Am J Surg. 1999;178(4):275-81.
42) Petrowsky H, Gonen M, Jarnagin W, et al. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg. 2002;235(6):863-71.
43) 別府 透,松田貞士,前田健晴,他:転移性肝癌へのマイクロ波凝固療法の応用.外科治療 2000;83:237-42.
44) Shibata T, Niinobu T, Ogata N, et al. Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma. Cancer. 2000;89(2):276-84.
45) Goya T, Miyazawa N, Kondo H, et al. Surgical resection of pulmonary metastases from colorectal cancer. 10-year follow-up. Cancer. 1989;64(7):1418-21.
46) McCormack PM, Burt ME, Bains MS, et al. Lung resection for colorectal metastases. 10-year results. Arch Surg. 1992;127(12):1403-6.
47) Ike H, Shimada H, Ohki S, et al. Results of aggressive resection of lung metastases from colorectal carcinoma detected by intensive follow-up. Dis Colon Rectum. 2002;45(4):468-73; discussion 473-5.
48) Okumura S, Kondo H, Tsuboi M, et al. Pulmonary resection for metastatic colorectal cancer: experiences with 159 patients. J Thorac Cardiovasc Surg. 1996;112(4):867-74.
49) Ike H, Shimada H, Togo S, et al. Sequential resection of lung metastasis following partial hepatectomy for colorectal cancer. Br J Surg. 2002;89(9):1164-8.
50) Ambiru S, Miyazaki M, Ito H, et al. Resection of hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer. 1998 Jan 15;82(2):274-8.
51) Saito Y, Omiya H, Kohno K, et al. Pulmonary metastasectomy for 165 patients with colorectal carcinoma: A prognostic assessment. J Thorac Cardiovasc Surg. 2002;124(5):1007-13.
52) McAfee MK, Allen MS, Trastek VF, et al. Colorectal lung metastases: results of surgical excision. Ann Thorac Surg. 1992;53(5):780-5; discussion 785-6.
53) Kandioler D, Kromer E, Tuchler H, et al. Long-term results after repeated surgical removal of pulmonary metastases. Ann Thorac Surg. 1998;65(4):909-12.
54) Sakamoto T, Tsubota N, Iwanaga K, et al. Pulmonary resection for metastases from colorectal cancer. Chest. 2001;119(4):1069-72.
55) Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494-500.
56) Robinson BJ, Rice TW, Strong SA, et al. Is resection of pulmonary and hepatic metastases warranted in patients with colorectal cancer? J Thorac Cardiovasc Surg. 1999;117(1):66-75; discussion 75-6.
57) 森谷宜皓,山口高史,赤須孝之,他:骨盤内局所再発癌に対する積極的外科治療.臨外 2001;56:759-65.
58) 亀岡信悟,小川真平:治療方針確定のための検査計画.杉原健一(編),再発大腸癌治療ガイドブック,東京,南江堂;2003:77-83.
59) Temple WJ, Saettler EB. Locally recurrent rectal cancer: role of composite resection of extensive pelvic tumors with strategies for minimizing risk of recurrence. J Surg Oncol. 2000;73(1):47-58.
60) Tschmelitsch J, Kronberger P, Glaser K, et al. Survival after surgical treatment of recurrent carcinoma of the rectum. J Am Coll Surg. 1994;179(1):54-8.
61) National Institutes of Health Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264(11):1444-50.
62) Haller DG, Catalano PJ, MacDonald JS. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: Five year report of INT-0089 (ABS). Proc ASCO 1998;17:256a (abstr)
63) Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol. 1999;17(11):3553-9.
64) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet. 1995;345(8955):939-44.
65) Wolmark N, Wieand S, Lembersky B, et al. A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: Results of NSABP protocol C-06. Proc ASCO 2004;22:247s (abst#3508)
66) Cassidy J, Scheithauer W, Mckendrick J, et al: Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer(the X-ACT study): positive efficacy results of a phase III trial. Proc ASCO 2004;22:247s (abst#3509)
67) Kato T, Ohashi Y, Nakazato H, et al. Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trial. Langenbecks Arch Surg. 2002;386(8):575-81.
68) Akasu T, Moriya Y, Yoshida S, et al: Adjuvant oral uracil and tegafur (UFT) improves survival after complete mesorectal excision (ME) for pathologic TNM stage III rectal cancer (RC) : Results of the National Surgical Adjuvant Study (NSAS) --Colorectal Cancer (CC) 01 randomized trial. Pro ASCO 2004;23:251 (abst#3524)
69) Scheithauer W, Rosen H, Kornek GV, et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ. 1993;306(6880):752-5.
70) Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ. 2000;321(7260):531-5.
71) de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938-47.
72) Kohne CH, Wils J, Lorenz M, et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol. 2003;21(20):3721-8.
73) Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23-30.
74) Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229-37.
75) Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol. 1987;5(10):1559-65.
76) 吉野正曠,太田和雄,栗原 稔,他:多施設共同研究による大量 l-leucovorin・5-FU 併用療法の進行結腸・直腸癌に対する後期第II相試験(東日本グループ).癌と化学療法 1995;22(6):785-92.
77) Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355(9209):1041-7.
78) Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343(13):905-14.
79) Saltz LB, Niedzwiecki D, Hollis D, et al: Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (Intergroup trial CALGB C89803). Proc ASCO 2004;22:245s (abst#3500)
80) Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998;352(9138):1413-8.
81) Douillard JY, Hoff PM, Skillings JR, et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2002;20(17):3605-16.
82) Carmichael J, Popiela T, Radstone D, et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2002;20(17):3617-27.
83) Shirao K, Hoff PM, Ohtsu A, et al. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. J Clin Oncol. 2004;22(17):3466-74.
84) Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19(8):2282-92.
85) Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19(21):4097-106.
86) Ohtsu A, Baba H, Sakata Y, et al. Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer. 2000;83(2):141-5.
87) Shirao K, Ohtsu A, Takada H, et al. Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer. 2004;100(11):2355-61.
88) Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. Meta-Analysis Group in Cancer. J Natl Cancer Inst. 1996;88(5):252-8.
89) Nakfoor BM, Willett CG, Shellito PC, et al. The impact of 5-fluorouracil and intraoperative electron beam radiation therapy on the outcome of patients with locally advanced primary rectal and rectosigmoid cancer. Ann Surg. 1998;228(2):194-200.
90) Strassmann G, Walter S, Kolotas C, et al. Reconstruction and navigation system for intraoperative brachytherapy using the flab technique for colorectal tumor bed irradiation. Int J Radiat Oncol Biol Phys. 2000;47(5):1323-9.
91) Skibber JM, Hoff PM, Minsky BD, et al: Cancer of the Rectum. In: Devita VT, Hellman S, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology (6th ed). Philadelphia, Lippincott, Williams and Wilkins;2001:1271-318.
92) Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med. 1997;336(14):980-7.
93) Camma C, Giunta M, Fiorica F, et al. Preoperative radiotherapy for resectable rectal cancer: A meta-analysis. JAMA. 2000;284(8):1008-15.
94) Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet. 2001;358(9290):1291-304.
95) Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638-46.
96) van de Velde CJ: Preoperative radiotherapy and TME-surgery for rectal cancer: detailed analysis in relation to quality control in a randomized trial. Proc ASCO 2002;21:127a.
97) Francois Y, Nemoz CJ, Baulieux J, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol. 1999;17(8):2396-402.
98) Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731-40.
99) Wolmark N, Wieand HS, Hyams DM, et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst. 2000;92(5):388-96.
100) National Institutes of Health Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264(11):1444-50.
101) O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 1994;331(8):502-7.
102) Smalley SR, Benedetti J, Williamson S, et al. Intergroup 0144-phase III trial of 5-FU based chemotherapy regimens plus radiotherapy (XRT) in postoperative adjuvant rectal cancer. Bolus 5-FU vs. prolonged venous infusion (PVI) before and after XRT+PVI vs. bolus 5-FU+leucovorin (LV) +Levamisone (LEV) before and after XRT+bolus 5-FU+LV. Proc ASCO 2003;22:251.
103) Gervaz PA, Wexner SD, Pemberton JH. Pelvic radiation and anorectal function: introducing the concept of sphincter-preserving radiation therapy. J Am Coll Surg. 2002;195(3):387-94.
104) Temple LK, Wong WD, Minsky B. The impact of radiation on functional outcomes in patients with rectal cancer and sphincter preservation. Semin Radiat Oncol. 2003;13(4):469-77.
105) Wong CS, Cummings BJ, Brierley JD, et al. Treatment of locally recurrent rectal carcinoma--results and prognostic factors. Int J Radiat Oncol Biol Phys. 1998;40(2):427-35.
106) Lingareddy V, Ahmad NR, Mohiuddin M. Palliative reirradiation for recurrent rectal cancer. Int J Radiat Oncol Biol Phys. 1997;38(4):785-90.
107) Bates T. A review of local radiotherapy in the treatment of bone metastases and cord compression. Int J Radiat Oncol Biol Phys. 1992;23(1):217-21.
108) Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol. 1991;9(3):509-24.
109) Wu JS, Wong R, Johnston M, et al. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys. 2003;55(3):594-605.
110) 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Bone Pain Trial Working Party. Radiother Oncol. 1999;52(2):111-21.
111) Steenland E, Leer JW, van Houwelingen H, et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol. 1999;52(2):101-9.
112) Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1980;6(1):1-9.
113) Kurtz JM, Gelber R, Brady LW, et al. The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1981 Jul;7(7):891-5.
114) Flickinger JC, Kondziolka D, Lunsford LD, et al. A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis. Int J Radiat Oncol Biol Phys. 1994;28(4):797-802.
115) World Health Organization: Cancer Pain Relief. WHO, Geneva, 1986.
116) Bruinvels DJ, Stiggelbout AM, Kievit J, et al. Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg. 1994;219(2):174-82.
117) Smith TJ, Bear HD. Standard follow-up of colorectal cancer patients: finally, we can make practice guidelines based on evidence. Gastroenterology. 1998;114(1):211-3.
118) Renehan AG, Egger M, Saunders MP, et al. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ. 2002;324(7341):813-6.
119) Kjeldsen BJ, Kronborg O, Fenger C, Jorgensen OD. A prospective randomized study of follow-up after radical surgery for colorectal cancer. Br J Surg. 1997;84(5):666-9.
120) Rosen M, Chan L, Beart RW Jr, Vukasin P, Anthone G. Follow-up of colorectal cancer: a meta-analysis. Dis Colon Rectum. 1998;41(9):1116-26.
121) McArdle C. ABC of colorectal cancer: effectiveness of follow up. BMJ. 2000;321(7272):1332-5.
122) Fleischer DE, Goldberg SB, Browning TH, et al. Detection and surveillance of colorectal cancer. JAMA. 1989;261(4):580-5.
123) Barillari P, Ramacciato G, Manetti G, et al. Surveillance of colorectal cancer: effectiveness of early detection of intraluminal recurrences on prognosis and survival of patients treated for cure. Dis Colon Rectum. 1996;39(4):388-93.
124) 上野秀樹,橋口陽二郎,望月英隆:大腸癌術後至適フォローアップに関する方法と意義.杉原健一(編),再発大腸癌治療ガイドブック,東京,南江堂;2003:19-25.
125) Berman JM, Cheung RJ, Weinberg DS. Surveillance after colorectal cancer resection. Lancet. 2000;355(9201):395-9.

 

 
ページトップへ

ガイドライン解説

close-ico
カテゴリで探す
五十音で探す

診療ガイドライン検索

close-ico
カテゴリで探す
五十音で探す